Myeloperoxidase gene-463G > a polymorphism and premature coronary artery disease

HUMAN AND MEDICAL GENETICS

SHORT COMMUNICATION

Myeloperoxidase gene-463G > A polymorphism and premature coronary artery disease

Chen Zhong^{I, *}; Yin Quanzhong^{II, *}; Ma Genshan^I; Zhang Hua^II; Zheng Ruolong^II; Wang Jiahong^I; Gao Chunheng^II

^IDepartment of Cardiology, The Affiliated ZhongDa Hospital of Southeast University, Nanjing, P.R. China

^IIDepartment of Cardiology, The Affiliated JiangYin Hospital of Southeast University, Jiangyin, P.R. China

^{Send correspondence to}

ABSTRACT

We investigated the association between myeloperoxidase gene -463G > A polymorphism and premature coronary artery disease (CAD) in two Chinese population samples: 229 patients and 230 controls. Genotypes were determined by ligase detection reaction-polymerase chain reaction sequencing and the grouping technique. We found lower frequencies of both the A/A genotype and the A allele in patients (p < 0.05). Multivariate logistic regression showed that the risk of premature CAD in subjects carrying the AA genotype was reduced by 83% in relation to individuals carrying the G/G genotype (OR = 0.172, 95% CI: 0.057-0.526, p = 0.002). Our results indicate that -463G > A polymorphism of the myeloperoxidase gene is associated with premature CAD in Chinese individuals, suggesting that the AA genotype is a protective factor against premature CAD.

Key words: premature coronary artery disease, myeloperoxidase, protective genetic polymorphism.

Myeloperoxidase (MPO) is a peroxidase enzyme produced by white blood cells (mainly neutrophil granulocytes and mononuclear cells). It represents a class of hemeproteins belonging to the heme peroxidase family. Several single nucleotide polymorphisms (SNPs) are present at sp1 binding sites in the promoter region of the MPO gene, including variants -463G/A, -129G/A, -V53F, -A332V, -638C/A, I642L, and IVS11-2A/C. To date, several studies have shown that the -463G/A, -129G/A, -V53F, -A332V, and -638C/A SNPs and MPO levels are risk factors in coronary artery disease (CAD) (Nikpoor et al., 2001; Brennan et al., 2003; Chevrier et al., 2003, 2006; Rutgers et al., 2003; Nicholls and Hazen, 2005; Stefanescu et al., 2008). Although MPO gene -463G > A polymorphism was first proven to be associated with CAD in a study by Nikpoor et al., (2001), the inclusion criteria used were disputable, since coronary stenosis of > 30% qualified this as being a CAD case. More importantly, genetic factors for CAD may be easier to detect in younger than in older groups, for in the latter many coexisting environmental factors might contribute to the progress of CAD. Studies conducted with younger CAD patients would thus help to reveal genetic factors relevant to CAD, if existent. Furthermore, to date no reports have dealt with the association between MPO gene -463G > A polymorphism and premature CAD. This was the aim of the present study.

From October, 2005 to May, 2008, 459 patients scheduled to undergo coronary angiography (CAG) for chest discomfort or suspected CAD, were enrolled in this study. 229 patients (men aged 36-54 years and women aged 39-64 years) with documented premature CAD (Kareinen et al., 2001) constituted the case group. CAD was considered to be premature if occurring in men with less than 55 years of age and women with less than 65 years at the time of diagnosis. Patients with CAD presented stenosis (> 50%) in at least one main coronary artery or had undergone myocardial infarction defined according to WHO criteria (WHO, 1990). 230 age- and sex-matched patients without detectable coronary stenosis in CAG were used as controls. All patients presenting infectious diseases, valvular and congenital heart disease, the X syndrome, connective tissue disease, rheumatism, malignant tumor, trauma, severe liver or kidney disease, or non-coronary artery thrombotic disease, or who were making use of anti-inflammatory drugs, were excluded from the study.

Anthropometric measurements and blood pressure determination were performed according to standard protocols. Body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters. Information on smoking habits and family history was obtained from all sampled individuals. The study protocol was approved by the Ethics Committee of the affiliated Zhong Da Hospital of Southeast University, all participants giving prior informed consent.

Venous blood was drawn from fasting subjects with 0.1% EDTA. One sample from each subject was used to analyze fasting blood sugar content (FBS), total cholesterol (TC), triglycerides (TG), LDL-cholesterol, HDL-cholesterol (HDL-C), apolipoprotein A1 (apoA1), apolipoprotein B (apoB) and lipoprotein a [Lp(a)]. A further sample was centrifuged (3,000 rpm for 15 min), the blood cells then being separated and stored in micro-tubes -70 °C for genomic DNA extraction. Plasma concentrations of TC, TG, HDL-C, and LDL-C were determined by standard biochemical methods through using a chemistry analyzer (Beckman Coulter SYNCHRON LX20 Clinical System, Fullerton, CA, USA).

DNA was obtained from blood cells by means of a whole-blood genome DNA extraction reagent kit [Axygene Biotechnology (Hangzhou) Limited (Hangzhou City, China)], according to manufacturer's instructions.

Genotyping was performed through ligase detection reaction (LDR) (Favis et al., 2000; Xiao et al., 2006) and polymerase-chain reaction (PCR) sequencing-type technology. Primer sequence included the use of upstream (5'-CGG TAT AGG CAC ACA ATG GTG AG-3') and downstream (5'-GCA ATG GTT CAA GCG ATT CTT C-3') primers. The PCR product was a 350 bp fragment including -463G > A SNP. Probe sequences used were P-G AAGAATCGCTTGAACCATTGCACATTTTTTTTTTTTTTTT – FAM, TTTTTTTTTTTTTTTCCCAGCTACTC GGGAGGCTCAGGCG,TTTTTTTTTTTTTTTTTTTCCCAGCTACTCGGGAGGCTCAGGCA for rs2333227 SNP modified, rs2333227_C and rs2333227_T, respectively. A Tris-EDTA loading buffer was prepared according to the molecular weight of the respective primer and fluorescent probe, and diluted to 50 pmol/µL as the stock solution. Thermal cycling of the PCR process was performed under the following conditions: 70 °C for 15 min, followed by 35 cycles of 94 °C for 30 s, 60 °C for 90 s, 72 °C for 1 min and a final extension of 72 °C for 10 min. PCR products were visualized after electrophoresis on 3% agarose gel. LDR was carried out under the following conditions: 95 °C for 2 min, followed by 35 cycles of 94 °C for 30 s and 60 °C for 2 min. The sequence was detected and genotypes were obtained through a sequencing system (ABI377, Application Biotechnology Corporation).

Statistical analyses were undertaken using SPSS 12.0 software and included descriptive statistics, Student's t-tests, comparisons of gene and genotype frequencies between the two groups, regression and multivariate analyses, and the calculation of odd-ratios with corresponding 95% confidence intervals.

The analysis of baseline characteristics, lipids, and glucose levels in patients with premature CAD and in the control group is shown in Table 1. The prevalence of smoking (44.1% vs. 23.5%), hypertension (64.2% vs. 51.7%), diabetes (22.3% vs. 11.7%), and a family history of CAD (36.7% vs. 21.7%), were significantly higher among patients than in the control group. The levels of FBS, TC, TG, LDL-C, apoB, and Lp(a) in the case group were significantly higher than those in the control group. No significant differences were detected in the levels of HDL-C and apoA1, as well as in preference by sex, average age and body mass indexes between cases and controls.

The polymorphism frequency distribution between the case and control groups is shown in Table 2. The GG genotype was found to be the most frequent genotype in both cases (66.4%) and controls (58.7%). Frequencies of the AA genotype and the A allele were significantly lower among patients than controls.

With respect to relationship between risk factors, MPO gene -463G > A polymorphism and premature CAD (Table 3), no significant differences were detected for BMI, FBS, all lipid parameters, hypertension, smoking, diabetes and a family history of CAD, when the genotypes of cases and controls were compared. Among all the covariates examined as potential confounders, only TC, diabetes mellitus, smoking and a family history of CAD contributed to the final multivariate model. The other variables, including BMI, FBS, TG, apolipoproteins, and hypertension, were not identified as independent variables. Adjusting to these covariates unmasked a significant association between MPO gene -463G > A genotypes and premature CAD. In patients carrying the AA genotype, the risk of premature CAD was reduced by 83% in relation to that of individuals carrying the G/G genotype (OR = 0.172, 95% CI: 0.057~0.526, p = 0.002).

We detected a significantly decreased risk of premature CAD in those individuals among native Chinese bearing the MPO gene -463 AA genotype. The MPO gene is located in chromosome 17q23-q24, and its expression is regulated by nutrilites (Denzler et al., 1997). The MPO -463G > A polymorphism, located at the promoter region, was first detected by Austin et al. (1993) in a study on acute myeloid leukemia patients. More recently, this same gene polymorphism was proven to be a risk of both CAD (Nikpoor et al., 2001) and cardiovascular events in CAD patients, the A allele being associated with less probability of developing cardiovascular disease (Asselbergs et al, 2004). The patients used in these studies were significantly older and the angiography criteria for CAD cases were disputable due to coronary stenosis of > 30% being qualified as a CAD case (Nikpoor et al., 2001). Since genetic factors for CAD may be easier to detect in younger groups than in older ones, we assumed that this gene could be closely related with premature CAD. Indeed, by using groups of younger subjects in our case-control study, we found that the risk of premature CAD was significantly reduced in Chinese patients with the AA genotype, in accordance with the results obtained for CAD by Nikpoor et al. (2001) when using older subjects.

It has been reported that MPO gene -463G > A polymorphism is related to changes in lipid levels (Nikpoor et al., 2001), and is a mechanism that may be involved in the oxidation of low-density lipoprotein, the high levels of MPO increasing the brittleness of artery plaques, thereby converting the plaque from the stable to the unstable state, thus increasing the risk of acute coronary syndrome (Sugiyama et al., 2001; Ndrepepa et al., 2008). The MPO -463A allele could interfere with the binding sites of the sp1 transcription factor, by reducing the level of MPO gene expression in its role in atherosclerotic plaque formation, thus having a definite impact on the risk of CAD. Meanwhile, MPO could promote the oxidation of HDL-C and affect the reverse transport role of cholesterol, thereby interfering in the development of atherosclerosis. The multivariate logistic regression that we performed showed that TC, diabetes mellitus, smoking and a family history of CAD are independent predictors of premature CAD, thus confirming that these are really traditional cardiovascular risk factors contributing independently to this disease (Schaefer et al., 1994; Bostom et al., 1996).

Our study and the results thence naturally present certain limitations, since the study-group was obtained from a single hospital in Southeast China, and the samples might not include all the characteristics of patients from other centers. It is also generally accepted that CAD is a disease produced by both multiple genes and environmental factors, and many other genes could be potential candidates for this sickness. Furthermore, since the MPO AA genotype is relatively infrequent, the actual value of genotype detection in the primary prevention of CAD may be disputable.

Acknowledgments

This study was supported by grants from the Ministry of Education of P.R. China and the Nanjing Scientific Development Project (2006ZD016).

Received: August 6, 2008; Accepted: November 6, 2008.

Associate Editor: Paulo A. Otto

References

• Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA and Tio RA (2004) Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 116:429-430.
• Austin GE, Lam L, Zaki SR, Chan WC, Hodge T, Hou J, Swan D, Zhang W, Racine M, Whitsett C, et al. (1993) Sequence comparison of putative regulatory DNA of the 5'flanking region of the myeloperoxidase gene in normal and leukemic bone marrow cells. Leukemia 7:1445-1450.
• Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, Schaefer EJ and Castelli WP (1996) Elevated plasma lipoprotein (a) and coronary artery disease in man aged 55 years and younger. A prospective study. JAMA 276:544-546.
• Brennan ML and Hazen SL (2003) Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 14:353-359.
• Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, et al. (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349:1595-1604.
• Chevrier I, Stücker I, Houllier AM, Cenée S, Beaune P, Laurent-Puig P and Loriot MA (2003) Myeloperoxidase: New polymorphisms and relation with lung cancer risk. Pharmacogenetics 13:729-739.
• Chevrier I, Tregouet DA, Massonnet-Castel S, Beaune P and Loriot MA (2006) Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: Genetic determinants for atherosclerosis. Atherosclerosis 188:150-154.
• Denzler KL, Levin WJ, Lee JJ and Lee NA (1997) The murine eosinophil peroxidase maps to chromosome 11. Mamm Genome 8:381-382.
• Favis R, Day JP, Gerry NP, Phelan C, Narod S and Barany F (2000) Universal DNA array detection of small insertions and deletions in BRCA1 and BRCA2. Nat Biotechnol 18:561-564.
• Kareinen A, Viitanen L, Halonen P, Lehto S and Laakso M (2001) Cardiovascular risk factors associated with insulin resistance cluster in families with early-onset coronary artery disease. Arterioscler Thromb Vasc Biol 21:1346-1352.
• Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Schömig A and Kastrati A (2008) Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 38:90-96.
• Nicholls SJ and Hazen SL (2005) Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 25:1102-1111.
• Nikpoor B, Turecki G, Fournier C, Théroux P and Rouleau GA (2001) A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 142:336-339.
• Rutgers A, Heeringa P, Giesen JE, Theunissen RT, Jacobs H and Tervaert JW (2003) Neutrophil myeloperoxidase activity and the influence of two single-nucleotide promoter polymorphisms. Br J Haematol 123:536-538.
• Schaefer EJ, Genest Jr JJ, Ordovas JM, Salem DN and Wilson PW (1994) Familial lipoprotein disorders and premature coronary artery disease. Atherosclerosis 108:S41-S54.
• Stefanescu A, Braun S, Ndrepepa G, Koppara T, Pavaci H, Mehilli J, Schömig A, Kastrati A, Stefanescu A, Braun S, et al. (2008) Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J 155:356-360.
• Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW and Libby P (2001) Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158:879-891.
• WHO (1990) MONICA Manual; CVD/MNC. World Health Organization, Geneva.
• Xiao Z, Xiao J, Jiang Y, Zhang S, Yu M, Zhao J, Wei D and Cao H (2006) A novel method based on ligase detection reaction for low abundant YIDD mutants detection in hepatitis B virus. Hepatol Res 34:150-155.

*

These two authors contributed equally to this paper.

Publication Dates

• Publication in this collection
  13 Mar 2009
• Date of issue
  2009

History

• Accepted
  06 Nov 2008
• Received
  06 Aug 2008